Vandria

Vandria develops first-in-class small molecules targeting mitochondrial function and chronic inflammation to treat age-related and chronic diseases. The company's pipeline includes assets for neurodegenerative, muscle, lung, and liver conditions. Its lead clinical candidate, VNA-318, is an orally available small molecule that has completed Phase I clinical studies for potential use in Alzheimer’s disease.